Latest Breaking News On - Promising new - Page 11 : comparemela.com

Significant Progress Made as Numinus-Sponsored PRIME Study on Psilocybin-Assisted Psychotherapy for Opioid, Stimulant and/or Alcohol Use Disorders Enters Pre-Implementation Stage Numinus Wellness (OTC:LKYSD) and  Syreon Corporation, a global contract research organization with expertise in conducting clinical trials across a broad range of diseases, are pleased to share that significant progress has been made in the single-arm, open-label compassionate access1 trial of Psilocybin-Research Intervention with Motivational Enhancement (PRIME) for substance use disorders. The study will contribute to a growing body of research to inform larger randomized controlled trials for these indications. The study will take place in Vancouver and will enroll 30 individuals with opioid, stimulant and/or alcohol use disorders. Syreon is leading the trial as Clinical Research Organization (CRO) with Numinus as the trial sponsor.

United statesNew jerseyBritish columbiaChristian angermayerPeter thielJason zandbergSyreon corporationAtai life sciencesResearch interventionCompany was considering floatingClinical research organizationLobe sciencesCronos groupStem holdingsField trip healthCannabis countdown